• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Plexus (PLXS) Stock Faces Margin Pressure Despite Stronger Revenue

    Simply Wall St·07/30/2026 22:23:50
    語音播報

    Plexus entered this earnings release with a relatively high 35x P/E and a stock that had slipped over the past month, yet the immediate reaction was a muted 0.7% gain. That small move hides the real headline. Q3 revenue reached about US$1.3b while basic earnings per share landed near US$1.61, and together they point to the key pressure point for investors.

    The story this quarter is margin strain. Net profit margin for the last 12 months sits near 4%, and that slight squeeze is what the market is quietly pricing into Plexus today.

    Like Plexus’s revenue scale but uneasy about margins stuck near 4%? Take a look at our list of resilient companies in the same broad universe with stronger balance sheets and earnings power through the list of solid balance sheet and fundamentals stocks (46 results).

    Q3 2026 Earnings Summary

    • Revenue, Q3 2026 vs. Q3 2025: US$1,304.8m vs. US$1,018.3m (higher year on year)
    • Net Income, Q3 2026 vs. Q3 2025: US$43.0m vs. US$45.1m (slightly lower year on year)
    • Basic EPS, Q3 2026 vs. Q3 2025: US$1.61 vs. US$1.67 (slightly lower year on year)
    • Net Profit Margin, Trailing 12 Months vs. Prior Year: 4.0% vs. 4.1% (margins slightly compressed)

    Prefer clear charts instead of scrolling through more paragraphs and raw earnings tables? View Plexus’s full financial picture in a visual format that highlights its recent earnings and profitability trends in the company report for Plexus.

    NasdaqGS:PLXS Trailing 12-Month Revenue & Expenses Breakdown as at Jul 2026
    NasdaqGS:PLXS Trailing 12-Month Revenue & Expenses Breakdown as at Jul 2026

    Plexus Growth Story Meets Margin Reality

    Bulls argue Plexus can turn complex, regulated programs in Aerospace & Defense and Healthcare into multi year revenue and margin improvement. This quarter partly supports that view. Revenue reached about US$1.3b, comfortably above the prior year, which fits with the idea that the record program funnel in sectors like defense and medical devices is converting into shipped product.

    Where the bullish narrative hits resistance is profitability. Net income and basic EPS both edged lower versus Q3 2025 and the trailing net margin sits near 4%. For a thesis built on higher value, higher margin programs and better asset utilization, that is a modest result rather than a step change. The small 0.7% share price move after earnings, following a weak 30 day return, suggests investors see Plexus progressing on scale but still waiting for the clear margin lift the bull case anticipates.

    Compare Plexus’s growing revenue base with what institutional analysts actually expect from here. See the consensus price target analysis for Plexus to gauge whether Wall Street thinks this margin story has real upside or is already reflected in the price.

    Plexus Bears See Margin Targets Slipping

    The core bearish worry on Plexus is that heavy exposure to complex aerospace, defense and healthcare programs will not translate into clean margin and cash flow progress once the ramps hit the factory floor. This quarter gives those critics some support. Revenue moved higher to about US$1.3b, yet net income and basic EPS both edged lower versus Q3 2025 and the trailing net margin sits near 4%. That looks like a key milestone missed for a company leaning on higher value programs and prior operating margin expansion.

    Bears also warn that aggressive growth funnels can soak up working capital and capex, then leave shareholders with thinner returns if profitability stalls. The relatively flat margin profile against a larger revenue base fits that pattern. Combined with a share price that has fallen about 19% over 30 days, the market reaction aligns more with caution than with a thesis reset in favor of Plexus.

    With Plexus scaling complex programs while margins sit near 4%, it is fair to ask whether this represents early friction or a sign of deeper structural issues in the business model. Review our independent risk scoring and identify any hidden operational, financial or governance warning signs in the risk analysis for Plexus which shows 1 important warning sign.

    Stay Ahead With Simply Wall St

    If Plexus’s 4% margin profile and recent share price moves have your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for an entry point that fits your plan. After you take a position, use the Portfolio Command Center to cut through noise and focus on the most important updates to your holdings. For a broader view of sentiment and debate around Plexus and similar stocks, tap into the Community to see how other investors are thinking. By spotting potential catalysts and risks early, you can make more confident decisions and stay ahead of the market.

    Seeking Alternatives Beyond Plexus?

    Fresh stock ideas can move from quiet buildup to sharp breakout before most investors react. Use these under the radar lists while it matters and get in early.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.